Vaccine, Booster and Natural Antibody Binding to SARS-CoV-2 Omicron (BA.1) Spike Protein and Vaccine Efficacy
James-Pemberton, P. H.; Helliwell, M. W.; Olkhov, R. V.; Kohli, S.; Westlake, A. C.; Farrar, B. M.; Sutton, B. J.; Ager, N. D.; Shaw, A. M.
Show abstract
The SARS-CoV-2 Omicron variant (BA.1) has 25 unique mutations to the Spike glycoprotein, suggesting the efficacy of current vaccines against the new variant may be seriously degraded. A fully quantitative antibody binding study was performed for Spike Omicron (SO) and original Spike (S) proteins simultaneously on three cohorts of patients: convalescent following RT-PCR-confirmed infection in early 2020, double-vaccinated at [≥]2 weeks, and vaccine boosters. The average (mode) of the booster cohort response distributions were 15.1 mg/L and 13.4 mg/L for S and SO, respectively, compared with the significantly lower double-vaccinated average, S=2.4 mg/L, SO=2.0 mg/L, and natural infections average S=2.0 mg/L, SO = 1.8 mg/L. A preliminary epitope degradation screen was performed for a panel of antibodies raised to the S1 and S2 regions of the original S protein. The panel showed significant degradation to antibody epitopes in the S1 region. Differential antibody binding of the vaccine response to S and SO suggests vaccine efficacy may be reduced by up to 50% against the Omicron variant.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation 95%
- Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration 94%
- Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test? 93%
Similar papers in this journal
- SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 93%
- Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray 93%
- Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes 93%
Similar papers in this journal
- A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 97%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 93%
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity 93%
Similar papers in this journal
- 30-Minute Highly Multiplexed VaxArray Immunoassay for Pneumococcal Vaccine Antigen Characterization 93%
- SARS-CoV-2 epitope mapping on microarrays highlights strong immune-response to N protein region 93%
- The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination 93%
Similar papers in this journal
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability 94%
- Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen 93%
- Extended interval BNT162b2 vaccination enhances peak antibody generation in older people 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.